Board of Directors
In this section
Alan has more than 35 years of commercial and company leadership experience, building international businesses in the technology sector. Beginning his career in the aerospace industry, Alan later joined the oil exploration industry where he held key technical and strategic roles in product and market development. Alan brings great experience in strategic analysis and international business planning, detailed and effective operational abilities, negotiation skills, corporate finance, and investment.
Chief Executive Officer
Iain has been CEO of Arrayjet since 2010 and led the introduction of services which have reshaped the company. Iain joined Arrayjet in 2007 and held positions of Chief Operating Officer, Chief Science Officer and Senior Scientist. He has a molecular biology background and was previously a Research Fellow with Cancer Research UK (Dundee), holds PhD and Masters degrees from St Andrews University and an Honours degree from Edinburgh University.
Chief Operating Officer
Kirsty joined Arrayjet in November 2011 and as Chief Operating Officer she coordinates operations across the company. With over 15 years experience in Operations Management within the contract research (CRO) industry, Kirsty has worked at both Quintiles and Aptuit within the preclinical drug development field. During this time she helped establish and expand in vitro cardiovascular and ion channel services and latterly became Director of Pharmacology. Kirsty holds a PhD in pharmacology and a degree in physiology from the University of Glasgow.
Martin Ramsay joined Arrayjet in January 2013 in order to bring a deeper insight to the company finances. Appointed to the board in 2014, Martin brings his experience from Mpathy Medical, Lab901, Vitrology and ScoLocate. Martin also represents Archangel Informal Investments Ltd on the board as their investor’s director.
Dr. Joseph Keegan joined Arrayjet in 2017 and currently serves as a director and advisor to Interpace Diagnostics (Nasdaq: IDXG), as well as many privately-held life science companies, including as Chair of Labcyte, Inc., and also as a director at Carterra and Nanomedical Diagnostics. From 2007 until its sale to Pall Corporation in 2012, Dr. Keegan served as President and Chief Executive Officer of ForteBio, Inc. Dr. Keegan joined ForteBio from Molecular Devices Corporation, where he served as President and Chief Executive Officer from 1998 to 2007. Before Molecular Devices, Dr. Keegan held leadership positions at Becton Dickinson, Leica, Inc., and GE Medical Systems. He has also served on numerous public and private company boards of life science tools companies.
Dr. Keegan holds a Ph.D. in Physical Chemistry from Stanford University. Among other attributes, skills and qualifications, the Board believes Dr. Keegan is qualified to serve as a Director of the Company because of his deep knowledge of the industry and customers, as well as his extensive executive management experience and prior service on other private and public company boards.